Drug Process Licensing Associates Publishes Third Process Patent

September 19, 2011 - DALLAS, Texas - Drug Process Licensing Associates (DPLA) has announced the filing of their third process patent. This most recent patent has been filed for Sitagliptin, the active ingredient in Januvia (Merck), used to lower blood sugar levels in patients with type 2 diabetes. The patent will protect the manufacturing process for a period of 20 years.

Founded in 2010 along with chemist Dr. Milan Soukup from Hoffman La-Roche, Drug Process Licensing Associates evaluates existing manufacturing processes for active pharmaceutical ingredients and then creates new, novel and more cost effective alternative routes which are patented and then exclusively licensed to their clients.

This third patent for DPLA is yet another successful development for the growing company which recently filed manufacturing process patents for both Pregabalin (Lyrica - Pfizer) and Tadalafil (Cialis - Lilly).

"It is highly gratifying to receive patent protection for our proprietary process for this preparation method of Sitagliptin," stated co-founder of DPLA Ron Schwarz, "Our exclusive access to this resource is a major step forward for our company and will potentially further and strengthen Drug Process Licensing Associates' position as a market leader in the chemical and pharmaceutical industry."

Dr. Milan Soukup, Schwarz's co-founder in DPLA added, "We are excited about future growth and opportunities created as a result of the patent and the high-quality efforts of our program. The increase in visibility that each patent allots us in the industry is also important as we move forward in creating PHILL, our innovative PHarmaceutical InteLLigence database."

About Drug Process Licensing Associates

Drug Process Licensing Associates, LLC was founded in 2010 by Ron Schwarz and Dr. Milan Soukup. Drug Process Licensing Associates publishes the PHarmaceutical InteLLigence database called PHILL as well as developing new, novel and cost effective manufacturing processes for active pharmaceutical ingredients. Drug Process Licensing Associates, LLC is located at 12160 Abrams Rd, Suite 516 Dallas, TX 75243, U.S.A. For more information, visit www.drugprocess.com or call Ron Schwarz directly at +1 (214) 838-5749.

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.